Evidence map›Paper›PMID 27124644›Full record

ArticleCell cycle (Georgetown, Tex.)2017

Mesenchymal stromal cells having inactivated RB1 survive following low irradiation and accumulate damaged DNA: Hints for side effects following radiotherapy.

Nicola Alessio, Stefania Capasso, Giovanni Di Bernardo, Salvatore Cappabianca, Fiorina Casale, Anna Calarco, Marilena Cipollaro, Gianfranco Peluso, Umberto Galderisi

Open access · bronzeAbstract read
In one paragraph

Article in Cell cycle (Georgetown, Tex.), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
3.3field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. The Role of Mesenchymal Stem Cells in Radiation-Induced Lung Fibrosis.International journal of molecular sciences · 2019
    Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Relevance of 3d culture systems to study osteosarcoma environment.Journal of experimental & clinical cancer research : CR · 2018
    Review
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Nicola Alessioa Department of Experimental Medicine , Biotechnology and Molecular Biology Section, Second University of Naples , Naples , Italy.
Stefania Capassoa Department of Experimental Medicine , Biotechnology and Molecular Biology Section, Second University of Naples , Naples , Italy.
Giovanni Di Bernardoa Department of Experimental Medicine , Biotechnology and Molecular Biology Section, Second University of Naples , Naples , Italy.
Salvatore Cappabiancab Department "F. Magrassi - A. Lanzara" Second University of Naples , Naples , Italy.
Fiorina Casalec Dipartimento della Donna , del Bambino e di Chirurgia Generale e Specialistica, Second University of Naples , Naples , Italy.
Anna Calarcod Institute of Bioscience and Bioresources, CNR , Naples , Italy.
Marilena Cipollaroa Department of Experimental Medicine , Biotechnology and Molecular Biology Section, Second University of Naples , Naples , Italy.
Gianfranco Pelusob Department "F. Magrassi - A. Lanzara" Second University of Naples , Naples , Italy.
Umberto Galderisia Department of Experimental Medicine , Biotechnology and Molecular Biology Section, Second University of Naples , Naples , Italy.
University of Campania "Luigi Vanvitelli" · ITUniversity of Naples Federico II · ITInstitute of Biosciences and Bioresources · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Following radiotherapy, bone sarcomas account for a significant percentage of recurring tumors. This risk is further increased in patients with hereditary retinoblastoma that undergo radiotherapy. We analyzed the effect of low and medium dose radiation on mesenchymal stromal cells (MSCs) with inactivated RB1 gene to gain insights on the molecular mechanisms that can induce second malignant neoplasm in cancer survivors. MSC cultures contain subpopulations of mesenchymal stem cells and committed progenitors that can differentiate into mesodermal derivatives: adipocytes, chondrocytes, and osteocytes. These stem cells and committed osteoblast precursors are the cell of origin in osteosarcoma, and RB1 gene mutations have a strong role in its pathogenesis. Following 40 and 2000 mGy X-ray exposure, MSCs with inactivated RB1 do not proliferate and accumulate high levels of unrepaired DNA as detected by persistence of gamma-H2AX foci. In samples with inactivated RB1 the radiation treatment did not increase apoptosis, necrosis or senescence versus untreated cells. Following radiation, CFU analysis showed a discrete number of cells with clonogenic capacity in cultures with silenced RB1. We extended our analysis to the other members of retinoblastoma gene family: RB2/P130 and P107. Also in the MSCs with silenced RB2/P130 and P107 we detected the presence of cells with unrepaired DNA following X-ray irradiation. Cells with unrepaired DNA may represent a reservoir of cells that may undergo neoplastic transformation. Our study suggests that, following radiotherapy, cancer patients with mutations of retinoblastoma genes may be under strict controls to evaluate onset of secondary neoplasms following radiotherapy.

Indexed as

DNA DamageApoptosisCell CycleCell LineageCell SurvivalCell Transformation, NeoplasticCellular SenescenceColony-Forming Units AssayDNA RepairGene SilencingHistonesHumansMesenchymal Stem CellsRadiotherapyRetinoblastoma-Like Protein p107Retinoblastoma ProteinH2AX protein, humanHistonesRetinoblastoma-Like Protein p107Retinoblastoma ProteinApoptosisDNA damagemesenchymal stem cellssenescence

Identifiers

PMID27124644
PMCPMC5323029
OpenAlexW2343101570

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.